Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yuxi Yang, Shunpei Okada & Masayuki Sakurai. (2021) Adenosine-to-inosine RNA editing in neurological development and disease. RNA Biology 18:7, pages 999-1013.
Read now
Read now
Brian M Smith, William J Thomsen & Andrew J Grottick. (2006) The potential use of selective 5-HT2C agonists in treating obesity. Expert Opinion on Investigational Drugs 15:3, pages 257-266.
Read now
Read now
Michael J Bishop & Björn M Nilsson. (2003) New 5-HT2C receptor agonists. Expert Opinion on Therapeutic Patents 13:11, pages 1691-1705.
Read now
Read now
Michael Van Ameringen, Catherine Mancini, Peter Farvolden & Jonathan Oakman. (2000) Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opinion on Investigational Drugs 9:10, pages 2215-2231.
Read now
Read now
Articles from other publishers (49)
Jing Zhai, Joanne Huifen Koh & Tuck Wah Soong. (2022) RNA editing of ion channels and receptors in physiology and neurological disorders. Oxford Open Neuroscience 1.
Crossref
Crossref
Gal Warhaftig, Chaya Mushka Sokolik, Khen Khermesh, Yehuda Lichtenstein, Michal Barak, Tzofnat Bareli, Erez Y. Levanon & Gal Yadid. (2021) RNA editing of the 5-HT2C receptor in the central nucleus of the amygdala is involved in resilience behavior. Translational Psychiatry 11:1.
Crossref
Crossref
Nicholas M. Barnes, Gerard P. Ahern, Carine Becamel, Joël Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A. Cunningham, Kevin C. Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M. Goodfellow, Adam L. Halberstadt, Rachel M. Hartley, Ghérici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K. Lambe, Marcello Leopoldo, Finn Olav Levy, Sarah C. R. Lummis, Philippe Marin, Luc Maroteaux, Andrew C. McCreary, David L. Nelson, John F. Neumaier, Adrian Newman-Tancredi, Hugues Nury, Alexander Roberts, Bryan L. Roth, Anne Roumier, Gareth J. Sanger, Milt Teitler, Trevor Sharp, Carlos M. Villalón, Horst Vogel, Stephanie W. Watts & Daniel Hoyer. (2020) International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews 73:1, pages 310-520.
Crossref
Crossref
Philippe De Deurwaerdère, Abdeslam Chagraoui & Giuseppe Di Giovanni. 2021. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part B. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part B
161
264
.
Yuta Yoshino & Yogesh Dwivedi. (2020) Non-Coding RNAs in Psychiatric Disorders and Suicidal Behavior. Frontiers in Psychiatry 11.
Crossref
Crossref
Paul A Zarkowski. (2019) Relative prevalence of 10 types of pharmacodynamic interactions in psychiatric treatment. The International Journal of Psychiatry in Medicine 55:2, pages 82-104.
Crossref
Crossref
Sara Whitestone, Philippe De Deurwaerdère, Lynn Baassiri, Julien Manem, Youssef Anouar, Giuseppe Di Giovanni, Rahul Bharatiya & Abdeslam Chagraoui. (2019) Effect of the 5-HT2C Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study. International Journal of Molecular Sciences 20:12, pages 2925.
Crossref
Crossref
P. L. Naplekova, V. B. Narkevich, V. S. Kudrin, L. M. Kostochka & T. A. Voronina. (2017) Neurochemichal aspects of the pharmacological effect of 2,3,4-trimethoxy-N’-(8-methyl-8-azabicyclo[3.2.1.] octan-3-ylidene) benzohydrazide hydrochloride (LK-933). Neurochemical Journal 11:3, pages 242-245.
Crossref
Crossref
Jose M. Palacios, Angel Pazos & Daniel Hoyer. (2017) A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology 234:9-10, pages 1395-1418.
Crossref
Crossref
Philippe De Deurwaerdère & Giuseppe Di Giovanni. (2017) Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Progress in Neurobiology 151, pages 175-236.
Crossref
Crossref
Mary-Jeanne Kallman. 2018. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
173
.
A. Chagraoui, F. Thibaut, M. Skiba, C. Thuillez & M. Bourin. (2016) 5-HT2C receptors in psychiatric disorders: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 66, pages 120-135.
Crossref
Crossref
Giuseppe Di Giovanni & Philippe De Deurwaerdère. (2016) New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacology & Therapeutics 157, pages 125-162.
Crossref
Crossref
Mary Jeanne Kallman. 2016. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1069
1214
.
Leif Hertz, Douglas L. Rothman, Baoman Li & Liang Peng. (2015) Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Frontiers in Behavioral Neuroscience 9.
Crossref
Crossref
Mary Jeanne Kallman. 2014. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
175
.
Zhiyong Zhong, Yunqing Zhang, Hongying Han, Zheping Huang, Jihui Wang, Mingfeng Chen & Jinbei Zhang. (2014) Effects of Low-Dose Olanzapine on Duloxetine-Related Nausea and Vomiting for the Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology 34:4, pages 495-498.
Crossref
Crossref
Franck Chenu, Stacey Shim, Mostafa El Mansari & Pierre Blier. (2013) Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons. Journal of Psychopharmacology 28:2, pages 162-167.
Crossref
Crossref
Massimo Pierucci, Stephanie Chambers, Lucy Partridge, Philippe De Deurwaerdère & Giuseppe Di Giovanni. 2014. Nicotinic Receptors. Nicotinic Receptors
279
305
.
K. S. Rayevsky, V. B. Narkevich, P. M. Klodt & V. S. Kudrin. (2012) Effect of Combined Administration of Afobazole and 5-HT2b/2c Receptor Antagonist SB-200646A on Neurochemical Profile of Brain Structures in C57Bl/6 and BALB/c Mice. Bulletin of Experimental Biology and Medicine 153:5, pages 689-693.
Crossref
Crossref
Giuseppe Di Giovanni, Massimo Pierucci & Vincenzo Di Matteo. 2011. Applications of Microdialysis in Pharmaceutical Science. Applications of Microdialysis in Pharmaceutical Science
93
150
.
Katarzyna Stachowicz, Joanna Wiero?ska, Helena Domin, Shigeyuki Chaki & Andrzej Pilc. (2011) Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin-and GABA-dependent. Pharmacological Reports 63:4, pages 880-887.
Crossref
Crossref
Giuseppe Di Giovanni, Ennio Esposito & Vincenzo Di Matteo. 2011. 5-HT2C Receptors in the Pathophysiology of CNS Disease. 5-HT2C Receptors in the Pathophysiology of CNS Disease
215
247
.
Shao-wen Tian, Moshe Laudon, Li Han, Jun Gao, Fu-lian Huang, Yu-feng Yang & Hai-feng Deng. (2010) Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacologica Sinica 31:7, pages 775-783.
Crossref
Crossref
Giuseppe Di Giovanni, Ennio Esposito & Vincenzo Di Matteo. (2010) Role of Serotonin in Central Dopamine Dysfunction. CNS Neuroscience & Therapeutics 16:3, pages 179-194.
Crossref
Crossref
Atsuko Kimura, Paula L. Stevenson, Roderick N. Carter, Gavin MacColl, Karen L. French, J. Paul Simons, Raya Al-Shawi, Valerie Kelly, Karen E. Chapman & Megan C. Holmes. (2009)
Overexpression of 5-HT
2C
receptors in forebrain leads to elevated anxiety and hypoactivity
. European Journal of Neuroscience 30:2, pages 299-306.
Crossref
Crossref
Minati Singh, M. Bridget Zimmerman, Terry G. Beltz & Alan Kim Johnson. (2009) Affect-related behaviors in mice misexpressing the RNA editing enzyme ADAR2. Physiology & Behavior 97:3-4, pages 446-454.
Crossref
Crossref
Carine Becamel. (2008) 5-Hydroxytryptamine receptor 2C. AfCS-Nature Molecule Pages.
Crossref
Crossref
Colleen A. McClung. (2007) Circadian genes, rhythms and the biology of mood disorders. Pharmacology & Therapeutics 114:2, pages 222-232.
Crossref
Crossref
Judith A. Siuciak, Douglas S. Chapin, Sheryl A. McCarthy, Victor Guanowsky, Janice Brown, Phoebe Chiang, Ravi Marala, Terrell Patterson, Patricia A. Seymour, Andrew Swick & Philip A. Iredale. (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:2, pages 279-290.
Crossref
Crossref
Daniel Hoyer. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
15
.
Hans Gerhard Vogel. 2008. Drug Discovery and Evaluation. Drug Discovery and Evaluation
565
876
.
E. G. Kuznetsova, T. G. Amstislavskaya, V. V. Bulygina, M. A. Tibeikina & N. K. Popova. (2006) Effect of 5HT2C-receptor agonist MK-212 on blood corticosterone level and behavior in mice. Bulletin of Experimental Biology and Medicine 142:5, pages 594-597.
Crossref
Crossref
Vincenzo Micale, Anna Arezzi, Liborio Rampello & Filippo Drago. (2006) Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission. European Neuropsychopharmacology 16:7, pages 538-545.
Crossref
Crossref
E. G. Kuznetsova, T. G. Amstislavskaya, E. A. Shefer & N. K. Popova. (2006) Effect of 5-HT2C receptor antagonist RS 102221 on mouse behavior. Bulletin of Experimental Biology and Medicine 142:1, pages 76-79.
Crossref
Crossref
Mark J. Millan. (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 110:2, pages 135-370.
Crossref
Crossref
Anne Dekeyne. (2005) Behavioural Models for the Characterisation of Established and Innovative Antidepressant Agents. Therapies 60:5, pages 477-484.
Crossref
Crossref
Mark John Millan. (2005) Serotonin 5-HT2C Receptors as a Target for the Treatment of Depressive and Anxious States: Focus on Novel Therapeutic Strategies. Therapies 60:5, pages 441-460.
Crossref
Crossref
Mark J. Millan, Mauricette Brocco, Alain Gobert & Anne Dekeyne. (2004) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 177:4, pages 448-458.
Crossref
Crossref
Michel Bourin, Eric Dailly & Martine Hascöet. (2006) Preclinical and Clinical Pharmacology of Cyamemazine: Anxiolytic Effects and Prevention of Alcohol and Benzodiazepine Withdrawal Syndrome. CNS Drug Reviews 10:3, pages 219-229.
Crossref
Crossref
Donald J. AbrahamKevin S. Currie. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
525
597
.
Didier Cussac, Adrian Newman-Tancredi, Delphine Duqueyroix, Valérie Pasteau & Mark J. Millan. (2002)
Differential Activation of Gq/11 and Gi
3
Proteins at 5-Hydroxytryptamine
2C
Receptors Revealed by Antibody Capture Assays: Influence of Receptor Reserve and Relationship to Agonist-Directed Trafficking
. Molecular Pharmacology 62:3, pages 578-589.
Crossref
Crossref
Mauricette Brocco, Anne Dekeyne, Sylvie Veiga, Sylvie Girardon & Mark J Millan. (2002) Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. Pharmacology Biochemistry and Behavior 71:4, pages 667-680.
Crossref
Crossref
H. Gerhard Vogel, Wolfgang H. Vogel, Bernward A. Schölkens, Jürgen Sandow, Günter Müller & Wolfgang F. Vogel. 2002. Drug Discovery and Evaluation. Drug Discovery and Evaluation
385
593
.
Florence Clenet, Anouk De Vos & Michel Bourin. (2001) Involvement of 5-HT2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. European Neuropsychopharmacology 11:2, pages 145-152.
Crossref
Crossref
R. Andreatini, C. Blanchard, R. Blanchard, M.L. Brandão, A.P. Carobrez, G. Griebel, F.S. Guimarães, S.L. Handley, F. Jenck, J.R. Leite, J. Rodgers, L.C. Schenberg, C. Da Cunha & F.G. Graeff. (2001) The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis. Brazilian Journal of Medical and Biological Research 34:2, pages 145-154.
Crossref
Crossref
A Dekeyne, B Denorme, S Monneyron & M.J Millan. (2000) Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2C receptors. Neuropharmacology 39:6, pages 1114-1117.
Crossref
Crossref
François Jenck, Jean-Luc Moreau, Jürgen Wichmann, Heinz Stadler, James R. Martin & Michael Bös. 2000. Anxiolytics. Anxiolytics
119
137
.
Deborah A. Evrard & Boyd L. Harrison. 1999.
1
10
.